Skip to main content
. 2023 Aug 18;13(1):127. doi: 10.1038/s41408-023-00895-7

Fig. 2. Overall Survival and Progression-Free Survival after CAR-T Infusion by Risk Score.

Fig. 2

Overall Survival A and Progression-Free Survival B according to a novel risk score based on the presence of either increasing extranodal metabolic tumor volume (MTV) or increasing total lesion glycolysis (TLG) of the largest lesion (risk score 1) versus neither risk factor (risk score 0). TLG incorporates both volume and degree of PET avidity from a lesion, and may act as a metabolic measure of tumor bulk.